Fertility benefits company Progyny (NASDAQ: PGNY) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.3% year on year to $350.5 million. On the other hand, next quarter’s revenue guidance of $340 million was less impressive, coming in 3% below analysts’ estimates. Its non-GAAP profit of $0.55 per share was 6.2% above analysts’ consensus estimates.

Is now the time to buy PGNY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Progyny’s second quarter results were met with a negative market reaction, despite the company delivering revenue and non-GAAP profit above Wall Street expectations. CEO Peter Anevski attributed the quarter’s growth to continued demand from employers for family building and women’s health solutions, emphasizing strong retention and early client commitments. Management noted that higher engagement levels and operational efficiencies contributed to margin expansion, while a more pronounced summer seasonality affected sales volumes. CFO Mark S. Livingston acknowledged the importance of maintaining healthy margins and highlighted the company’s ability to invest in platform expansion while returning value to shareholders through share repurchases.

Looking ahead, management’s guidance reflects caution due to an expected continuation of pronounced seasonal patterns and a modest outlook for client activity in the coming quarter. Anevski explained that while early sales season commitments position Progyny well for client additions, the company is not expecting its new fully insured offering, Progyny Select, to contribute meaningfully in the near term. Livingston added that the investment program supporting future growth is forecast to taper after this year, with ongoing focus on cost control and margin stability. Management maintains confidence in long-term demand for fertility benefits but remains mindful of employment trends and client purchase timing.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to strong client retention, employer demand for cost-effective benefits, and operational efficiencies, while also addressing near-term headwinds from seasonality and industry cost pressures.

• Client retention and early commitments: Progyny reported that its largest clients renewed earlier than usual, reducing retention risk for the coming year and signaling confidence in the company’s solutions. Anevski highlighted that early client decisions span diverse industries and company sizes.

• Employer demand for cost control: Employers faced rising medical and pharmacy costs, leading to increased interest in fertility and women’s health benefits that offer measurable returns on investment. Anevski noted that Progyny’s transparent reporting and track record in cost management differentiate it from competitors.

• Seasonal impact on engagement: The quarter saw a more pronounced summer slowdown in member activity, which management described as typical but slightly stronger than in prior years. Livingston clarified that guidance reflects stable utilization patterns based on historical experience and improved forecasting algorithms.

• Margin improvement through efficiency: Gross margin expanded as a result of continued efficiencies in care management and reduced stock compensation expense. Livingston emphasized that investments in platform enhancements were balanced by operational discipline, supporting both profitability and future growth.

• Share repurchase activity: Progyny continued returning capital to shareholders, executing nearly $31.5 million in share repurchases during the quarter and lowering outstanding shares by approximately 12.5% since program inception. Management views this as a means to balance investment in growth with shareholder returns.

Drivers of Future Performance

Progyny’s outlook is shaped by seasonality, muted near-term client contribution from new offerings, and continued investment discipline as the company balances growth with profitability.

• Seasonal utilization patterns: Management expects the more pronounced summer seasonality to continue affecting engagement in the near term, but believes activity should normalize later in the year. Anevski explained that improved forecasting models and historical patterns support confidence in a rebound after the summer slowdown.

• Client acquisition and retention: The company’s guidance assumes continued strong performance in client retention and the addition of 1 million or more new covered lives, primarily from traditional self-insured employers. Anevski noted that most early commitments are from employers focused on cost control, especially in industries facing higher health benefit expenses.

• Investment taper and margin focus: Livingston stated that capital expenditures and related operating expenses tied to product and platform investments are expected to decrease after this year, supporting stable adjusted EBITDA margins. Future growth from new channels such as Progyny Select and health plan partnerships is expected to be modest in the near term, with greater impact anticipated in later years.

Catalysts in Upcoming Quarters

In the coming quarters, our team will be monitoring (1) whether engagement rebounds as seasonality wanes and member activity normalizes, (2) the pace of new client additions and retention, especially among large employers seeking cost control, and (3) the initial progress of new channel partnerships and Progyny Select. Demonstrated improvement in utilization and expanded platform adoption will serve as key indicators of execution.

Progyny currently trades at $25.73, down from $30.21 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.